DK2020999T3 - Sammensætninger omfattende alfa-ketoglutarat og deres anvendelse til modulering af muskelperformance - Google Patents

Sammensætninger omfattende alfa-ketoglutarat og deres anvendelse til modulering af muskelperformance

Info

Publication number
DK2020999T3
DK2020999T3 DK07728341.4T DK07728341T DK2020999T3 DK 2020999 T3 DK2020999 T3 DK 2020999T3 DK 07728341 T DK07728341 T DK 07728341T DK 2020999 T3 DK2020999 T3 DK 2020999T3
Authority
DK
Denmark
Prior art keywords
muscle performance
ketoglutarate
alpha
compositions
modulating muscle
Prior art date
Application number
DK07728341.4T
Other languages
English (en)
Inventor
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Application granted granted Critical
Publication of DK2020999T3 publication Critical patent/DK2020999T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK07728341.4T 2006-04-21 2007-04-20 Sammensætninger omfattende alfa-ketoglutarat og deres anvendelse til modulering af muskelperformance DK2020999T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL379512A PL379512A1 (pl) 2006-04-21 2006-04-21 Nowe metody i ich zastosowanie
PCT/EP2007/053882 WO2007122190A1 (en) 2006-04-21 2007-04-20 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance

Publications (1)

Publication Number Publication Date
DK2020999T3 true DK2020999T3 (da) 2011-11-21

Family

ID=38359362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07728341.4T DK2020999T3 (da) 2006-04-21 2007-04-20 Sammensætninger omfattende alfa-ketoglutarat og deres anvendelse til modulering af muskelperformance

Country Status (10)

Country Link
US (1) US20090069429A1 (da)
EP (1) EP2020999B1 (da)
JP (1) JP2009534360A (da)
CN (1) CN101426490B (da)
AT (1) ATE522210T1 (da)
DK (1) DK2020999T3 (da)
ES (1) ES2372207T3 (da)
HK (1) HK1131340A1 (da)
PL (2) PL379512A1 (da)
WO (1) WO2007122190A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013026706A2 (pt) * 2011-04-18 2016-12-27 Nestec Sa composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
WO2016083399A1 (en) * 2014-11-24 2016-06-02 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia
CN106963749A (zh) * 2017-03-23 2017-07-21 华南农业大学 α‑酮戊二酸（盐）在抗疲劳和提高肌肉运动力量方面的应用
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
EP3980000A4 (en) * 2019-06-10 2023-06-21 Buck Institute for Research on Aging METHODS AND COMPOSITIONS FOR MODIFYING A SECRETORY PHENOTYPE ASSOCIATED WITH SENESCENCE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
ITRM20010445A1 (it) * 2001-07-25 2003-01-27 Sigma Tau Healthscience Spa Alfa-chetoglutarati di principi attivi e composizioni che li contengono.
EP1638546A1 (en) * 2003-07-01 2006-03-29 Essentys AB Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition

Also Published As

Publication number Publication date
JP2009534360A (ja) 2009-09-24
PL2020999T3 (pl) 2012-01-31
ES2372207T3 (es) 2012-01-17
ATE522210T1 (de) 2011-09-15
EP2020999A1 (en) 2009-02-11
PL379512A1 (pl) 2007-10-29
CN101426490A (zh) 2009-05-06
CN101426490B (zh) 2011-01-12
WO2007122190A1 (en) 2007-11-01
EP2020999B1 (en) 2011-08-31
HK1131340A1 (en) 2010-01-22
US20090069429A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
UA100250C2 (uk) Інгібітори реплікації вірусу імунодефіциту людини
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DK2024367T3 (da) Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
WO2007092622A3 (en) Compositions and methods for treating bone
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201001639A1 (ru) Композиции и способы их получения и применения
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
EA200701995A1 (ru) Способы уменьшения кальцификации
DK2020999T3 (da) Sammensætninger omfattende alfa-ketoglutarat og deres anvendelse til modulering af muskelperformance
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.